DRS

Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements

Retrieved on: 
Tuesday, February 6, 2024
Skin cancer, COVID-19, Inflammation, Pneumonia, Immune system, SRT, Patient, BOCA, Dermatology, COVID, Rheumatoid arthritis, Radiation, Keloid, Poaceae, Physician, Malignancy, DRS, Radiation therapy, Education, Skin, Health, Medical imaging

BOCA RATON, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a new multi-faceted collaboration with CureRays, a radiation oncology specialist organization based in Atlanta and Grass Valley, Calif. 

Key Points: 
  • Under the collaboration, CureRays will provide Sensus’ dermatology customers with oversight and supervision to assure patient safety, quality, reliability of outcomes and conformance with regulatory requirements, in particular in states where regulations covering the use of ionizing radiation have been tightened.
  • In addition, CureRays will research new indications for Sensus’ superficial radiotherapy (SRT and IG-SRT), including inflammatory diseases.
  • We were anxious to help stem fatalities in any way we could, and we’ve been impressed with their commitment to patient care.
  • My goal is also to help further enhance patient selection against the risks and benefits of radiotherapy.”

Playmaker Capital Inc. Announces Closing of Acquisition by Better Collective

Retrieved on: 
Tuesday, February 6, 2024
Other Professional Services, Sports, Other Communications, Publishing, Media, Communications, Professional Services, Other Sports, Transfer, Indian stock exchange, Related, Entrepreneurship, Investment, TSX Venture Exchange, Nasdaq Stockholm, Nasdaq Copenhagen, Acquisition, DRS, Sale, Arrangement, Letter, National instrument, Organization, Security (finance)

Playmaker Capital Inc. (TSX-V: PMKR) (“Playmaker” or the “Company”), the digital sports media company that delivers authentic content experiences through its portfolio of sports media brands, is pleased to announce the closing of its previously announced plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”) with Better Collective A/S (“Better Collective”).

Key Points: 
  • Playmaker Capital Inc. (TSX-V: PMKR) (“Playmaker” or the “Company”), the digital sports media company that delivers authentic content experiences through its portfolio of sports media brands, is pleased to announce the closing of its previously announced plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”) with Better Collective A/S (“Better Collective”).
  • Jordan Gnat, Co-Founder and Chief Executive Officer of Playmaker, said “Today the Playmaker family begins the next phase of our journey by joining the Better Collective family.
  • A special thank you to Jesper, Christian and the Better Collective team for the confidence you have shown in our team.
  • Prior to closing of the Arrangement, Better Collective held no Common Shares.

Foundation Fighting Blindness Launches GYROS, a Natural History Study for People with Gyrate Atrophy

Retrieved on: 
Tuesday, February 6, 2024
Paratriathlon, Arginine, Visual impairment, Clinical trial, Wilmer Ophthalmological Institute, FDA, OAT, Associate, Plasma, Human services, Genetic distance, HHS, Government, Diet, Alanine transaminase, Tissue, Nyctalopia, Unitary state, Johns Hopkins University, Patient, Retina, Ornithine aminotransferase deficiency, DRS, Doctor of Philosophy, Research, MHS

COLUMBIA, Md. , Feb. 6, 2024 /PRNewswire/ -- `The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for inherited retinal diseases and dry age-related macular degeneration, is launching a natural history study for people with gyrate atrophy, a rare, vision-robbing inherited retinal disease. The lead investigators for the study are Mandeep S. Singh, MD, PhD, the Andreas C. Dracopoulos Professor of Ophthalmology and Associate Professor of Ophthalmology and Genetic Medicine at the Wilmer Eye Institute and David Valle, MD, Professor of Genetic Medicine and former director of the McKusick-Nathans Department of Genetic Medicine at Johns Hopkins University.

Key Points: 
  • GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.
  • , Feb. 6, 2024 /PRNewswire/ -- `The Foundation Fighting Blindness , the world's leading organization committed to finding treatments and cures for inherited retinal diseases and dry age-related macular degeneration, is launching a natural history study for people with gyrate atrophy, a rare, vision-robbing inherited retinal disease.
  • Known as the Gyrate Atrophy Ocular and Systemic Study (GYROS), the $3.5 million study is informing the design of future clinical trials for gyrate atrophy.
  • Gyrate atrophy is a progressive retinal disease that causes night blindness and loss of peripheral vision, in addition to severe childhood-onset myopia.

Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, SAN, Jacob (name), Patient, DRS

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 6th Annual Guggenheim Biotechnology Conference being held at the St. Regis in New York, New York.

Key Points: 
  • SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 6th Annual Guggenheim Biotechnology Conference being held at the St. Regis in New York, New York.
  • Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in a fireside chat on Thursday, February 8, 2024 at 11:00 am Eastern Time.
  • Drs.
  • Lim and Chacko will also participate in one-on-one investor meetings.

OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board

Retrieved on: 
Wednesday, January 31, 2024
Uveitis, Telecanthus, Research, University, Yale School of Medicine, Patient, Pain, Wilmer Ophthalmological Institute, Safety, FDA, NCP, Physician, DED, Eye, DRS, Bascom Palmer Eye Institute, Garden, Pharmaceutical industry

and Anat Galor, M.D., both from the Bascom Palmer Eye Institute, and Mark Milner, M.D., of the Goldman Eye in Palm Beach Gardens, Florida, have joined OKYO’s Scientific Advisory board.

Key Points: 
  • and Anat Galor, M.D., both from the Bascom Palmer Eye Institute, and Mark Milner, M.D., of the Goldman Eye in Palm Beach Gardens, Florida, have joined OKYO’s Scientific Advisory board.
  • Dr Victor Perez is a Director of Cornea Research at Bascom Palmer Eye Institute, at the University of Miami Miller School of Medicine.
  • He is a clinician-scientist investigator in the field of ocular immunology and ocular surface diseases and served as Director of Duke Eye Center’s Ocular Immunology Center before joining Bascom Palmer Eye Institute.
  • OKYO's Scientific Advisory Board now has an ideal blend of clinical expertise, including ocular surface disease and neuropathic corneal pain, from the leading experts in those fields."

2024 OREF Clinical Research Award Celebrates Study of Local Gene Therapy to Treat Osteoarthritis

Retrieved on: 
Friday, February 2, 2024
University, Visual analogue scale, DSM-IV codes, Cell, Investigational New Drug, Mayo Clinic, Research, Liver, Knee, DNA, Disease, OA, Patient, Pain, Safety, University of Minnesota, Swelling, FDA, Rheumatoid arthritis, Osteoarthritis, Arthritis, Food, Risk, DRS, Biology, WOMAC, University of Florida, Doctor of Philosophy, Cancer, Joint, Molecular medicine, Pharmaceutical industry

ROSEMONT, Ill. , Feb. 2, 2024 /PRNewswire/ -- The 2024 Orthopaedic Research and Education Foundation (OREF) Clinical Research Award was presented to Christopher H. Evans, PhD (Mayo Clinic), Steven C. Ghivizzani, PhD (University of Florida), and Paul D. Robbins, PhD (University of Minnesota), for their research on local gene therapy for osteoarthritis (OA).

Key Points: 
  • ROSEMONT, Ill. , Feb. 2, 2024 /PRNewswire/ -- The 2024 Orthopaedic Research and Education Foundation (OREF) Clinical Research Award was presented to Christopher H. Evans, PhD (Mayo Clinic), Steven C. Ghivizzani, PhD (University of Florida), and Paul D. Robbins, PhD (University of Minnesota), for their research on local gene therapy for osteoarthritis (OA).
  • Together, the team spearheaded the research from a laboratory concept to human clinical trials over the course of 30 years.
  • The OREF Award recognizes outstanding clinical research related to musculoskeletal disease or injury.
  • Evans, Ghivizzani and Robbins co-founded an arthritis gene therapy startup company, Genascence Corporation, which will help fund future clinical trials.

Nathaniel A. Dyment, PhD, Presented With 2024 Kappa Delta Young Investigator Award for Research on Formation, Maintenance and Repair of Tendons and Ligaments

Retrieved on: 
Friday, February 2, 2024
Growth, Cell, Embryo, Research, Element, Muscle contraction, Achilles tendon, Injury, Homeostasis, University of Pennsylvania, Anterior cruciate ligament reconstruction, Fibrocartilage, Ligament, DSM-IV codes, DRS, Tissue, Tendon, Doctor of Philosophy, University, Tonia, Medical imaging

The award recognizes outstanding clinical research related to musculoskeletal disease or injury by investigators under 40 years old.

Key Points: 
  • The award recognizes outstanding clinical research related to musculoskeletal disease or injury by investigators under 40 years old.
  • Unfortunately, clinicians and researchers lack biological benchmarks to assess the repairs of these tissues, hampering the development of new therapies.
  • "Therefore, the development of treatments to successfully repair or regenerate tendons is very difficult.
  • The degeneration that is happening in tendons can take decades to develop, making successful treatment of these injuries a big challenge.

PRMA Plastic Surgery Celebrates Remarkable Milestone: 12,000 Free Flap Breast Reconstructions

Retrieved on: 
Thursday, February 1, 2024
SAN, Abdomen, Survivor, Research, Patient safety, Patient, Breast cancer, Hope, DRS

SAN ANTONIO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- PRMA Plastic Surgery, a leading provider of reconstructive breast surgery, is proud to announce a momentous achievement in their mission to restore hope and confidence to breast cancer survivors. With an unwavering commitment to excellence, PRMA has successfully completed 12,000 free flap breast reconstructions, becoming synonymous with hope and restoration for survivors worldwide.

Key Points: 
  • SAN ANTONIO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- PRMA Plastic Surgery, a leading provider of reconstructive breast surgery, is proud to announce a momentous achievement in their mission to restore hope and confidence to breast cancer survivors.
  • With an unwavering commitment to excellence, PRMA has successfully completed 12,000 free flap breast reconstructions, becoming synonymous with hope and restoration for survivors worldwide.
  • With an unwavering commitment to excellence, PRMA has successfully completed 12,000 free flap breast reconstructions, becoming synonymous with hope and restoration for survivors worldwide.
  • For more information about PRMA Plastic Surgery and their commitment to breast cancer survivors, please visit http://www.prma-enhance.com or contact Tabetha Williams.

Health Net Awards $2 Million to Support 47 California Independent Physician Practices, Complementing Initiative from Department of Health Care Services

Retrieved on: 
Tuesday, January 30, 2024
Partnership, Health Net, CNC, Physician, Patient satisfaction, Health information management, Centene Corporation, PHC, EPT, DHCS, Demographics of Los Angeles, Health, Pediatrics, Equity, DRS, Medi-Cal, Health equity, Nursing

SACRAMENTO, Calif., Jan. 30, 2024 /PRNewswire/ -- Health Net, one of California's most experienced Medi-Cal managed care health plans and a wholly owned subsidiary of Centene Corporation (NYSE: CNC), announced $2 million in grants to 47 independent physician practices throughout California. Focused on increasing access to available funding from the Department of Health Care Services (DHCS), the grants will remove barriers that may limit physician practices' ability to take advantage of the Equity and Practice Transformation (EPT) Provider Direct Payment Program.

Key Points: 
  • SACRAMENTO, Calif., Jan. 30, 2024 /PRNewswire/ -- Health Net, one of California's most experienced Medi-Cal managed care health plans and a wholly owned subsidiary of Centene Corporation (NYSE: CNC), announced $2 million in grants to 47 independent physician practices throughout California.
  • The grants provided by Health Net will aid these independent physician practices in their endeavors to keep pace with the rapidly changing demands of the healthcare industry.
  • Physicians for a Healthy California (PHC), formerly known as the California Medical Association Foundation, has long supported physician practices and is an important partner for Health Net.
  • Beyond the grants awarded, Health Net remains committed to supporting quality improvements in independent physician practices.

Gen4 Dental Partners 2023 Year in Review

Retrieved on: 
Monday, January 22, 2024
Diamond, Mentorship, HR, CEREC, DSO, Family, Orthodontics, Laser, Health, Comfort Dental, Dentistry, Periodontology, Patient, Minneapolis–Saint Paul, DRS, Partnership, Align Technology, Dental care, Dentist, Dental implant

Tempe, AZ, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Gen4 Dental Partners, a Thurston Group portfolio company, has announced another year of explosive growth in 2023, welcoming 71 new doctors and 160 hygienists into the 2½-year-old Dental Service Organization (DSO).

Key Points: 
  • Tempe, AZ, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Gen4 Dental Partners, a Thurston Group portfolio company, has announced another year of explosive growth in 2023, welcoming 71 new doctors and 160 hygienists into the 2½-year-old Dental Service Organization (DSO).
  • “Gen4 Dental Partners continues to impress and outperform high growth targets,” said Patrick J. Haynes III, Chairman and CEO of Thurston Group.
  • The value proposition and differentiation of the platform has attracted the highest quality of partners across multiple dental specialties, which has positioned Gen4 as a market leader.”
    In 2023, Gen4 completed over 20 acquisitions comprising over 70 dentists across 40+ offices.
  • The 2023 LeGENd Awards recognized the most outstanding dental offices in the organization: Cassity Implants, Little Smiles, Beaumont Family Dentistry, and Gentling Dental Care.